Putnam Investments’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Putnam Investments’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,767	Closed	-$384K	–	1234
2023 Q2	$384K	Buy	+3,767	New	+$356K	﹤0.01%	1005

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Putnam Investments's RETA Position: Q3 2023 in Review

Putnam Investments sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 3,767 shares — an estimated $384K sold.

Putnam Investments first reported a position in RETA in Q2 2023 and held it in 1 quarter. The position peaked at $384K in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Putnam Investments reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Putnam Investments sold 3,767 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $384K.
Putnam Investments first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2023 and held it in 1 quarter.
Putnam Investments's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $384K in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Putnam Investments's 13F filing for Q3 2023, filed 14 Nov 2023.